bavdegalutamide   Click here for help

GtoPdb Ligand ID: 11512

Synonyms: ARV-110 | ARV110 | compound 406 [WO2018071606A1]
Compound class: Synthetic organic
Comment: Bavdegalutamide (ARV110) is a bifunctional degarder class compound (PROTAC). One end of the molecule binds to the androgen receptor and the other binds to the cereblon E3 ligase and directs the AR for proteasome-mediated degradation [1]. It has clinical potential as an oral therapy for metastatic castration-resistant prostate cancer. PubChem CID 134414307 represents the molecule without specified stereo chemistry.
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the CDK toolkit. All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 14
Hydrogen bond donors 2
Rotatable bonds 10
Topological polar surface area 181.17
Molecular weight 811.3
XLogP 4.78
No. Lipinski's rules broken 1
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

✖
Canonical SMILES N#Cc1ccc(cc1Cl)O[C@@H]1CC[C@H](CC1)NC(=O)c1ccc(nn1)N1CCC(CC1)CN1CCN(CC1)c1cc2C(=O)N(C(=O)c2cc1F)C1CCC(=O)NC1=O
Isomeric SMILES N#Cc1ccc(cc1Cl)O[C@@H]1CC[C@H](CC1)NC(=O)c1ccc(nn1)N1CCC(CC1)CN1CCN(CC1)c1cc2C(=O)N(C(=O)c2cc1F)C1CCC(=O)NC1=O
InChI InChI=1S/C41H43ClFN9O6/c42-31-19-28(4-1-25(31)22-44)58-27-5-2-26(3-6-27)45-38(54)33-7-9-36(48-47-33)51-13-11-24(12-14-51)23-49-15-17-50(18-16-49)35-21-30-29(20-32(35)43)40(56)52(41(30)57)34-8-10-37(53)46-39(34)55/h1,4,7,9,19-21,24,26-27,34H,2-3,5-6,8,10-18,23H2,(H,45,54)(H,46,53,55)/t26-,27-,34?
InChI Key CLCTZVRHDOAUGJ-SYVGMNBRSA-N
No information available.
Summary of Clinical Use Click here for help
ARV110 has been advanced to early clinical trial in patients with metastatic castration-resistant prostate cancer (mCRPC). In May 2019 the FDA granted fast track designation for mCRPC.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT03888612 Trial of ARV-110 in Patients With Metastatic Castration Resistant Prostate Cancer Phase 1/Phase 2 Interventional Arvinas Inc